Lesion-level dual-tracer PET biomarkers predict prognosis in multiple myeloma treated with CXCR4-directed radiopharmaceutical therapy
In our exploratory analysis, [¹⁸F]FDG-uptake within medullary concordant lesions was linked to both response and survival, while CXCR4-expressing medullary volume and sDmax added survival information. Concordance-aware, lesion-level quantification from dual-tracer PET/CT might present as a promising approach to aid risk stratification for CXCR4-directed RPT. However, initial findings of our hypothesis generating analysis warrant prospective validation in larger cohorts.
Authors
- Andreas K. Buck (ORCID: https://orcid.org/0000-0002-6447-0613)
- Niklas Dreher (ORCID: https://orcid.org/0000-0003-2921-8452)
- Kerstin Michalski (ORCID: https://orcid.org/0000-0001-8715-7788)
- Sabrina Kraus (ORCID: https://orcid.org/0000-0001-8954-4220)
- Song Xue
- Hermann Einsele
- Xiang Li
- Johanna S. Enke
- Constantin Lapa
- Marcus Hacker
Institutions
- University of Augsburg (DE)
- Capital Medical University (CN)
- Vienna General Hospital (AT)
- Universitätsklinikum Würzburg (DE)
- Medical University of Vienna (AT)
Publication Details
- Journal
- European Journal of Nuclear Medicine and Molecular Imaging
- Published
- 2026-02-18
- DOI
- https://doi.org/10.1007/s00259-026-07814-5
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Universität Wien
- Medizinische Universität Wien